Newswise — A study from the George Washington University unveils insights into the treatment experiences and perceptions of people living with a significantly disabling chronic inflammatory skin condition.
The condition known as hidradenitis suppurativa causes painful recurring boils and abscesses, most commonly in body fold such as armpits, in the groin area or under the breasts, as well as chest and back, that often leads to significant and movement restrictive scarring and disfigurement.
There are many off-label treatment options available but only two that are FDA approved at the time of the study.
“Our goal with this study was to highlight the multifaceted positive impact of new FDA treatments on those living with hidradenitis and the importance of pharma investment in this space which is finally happening,” said Dr. Adam Friedman, Professor and Chair of Dermatology at the GW School of Medicine and Health Sciences. Sadly though, we also found that there are still significant gaps in care and dissatisfaction with current treatment approaches.”
The study by researchers in the Department of Dermatology at the GW School of Medicine & Health Sciences in partnership with HS Connect, surveyed over 500 people who have this painful condition.
Key Findings:
- Only 18% of respondents expressed satisfaction with their current treatment regimen.
- 74% of respondents were unaware of FDA-approved treatments and 56% reported that their healthcare provider had not discussed these options with them.
- 60% of respondents emphasized the importance of FDA-approved therapies, believing they would lead to improved physical health, mental health and personal relationships.
The Study, published in the Journal of Drugs in Dermatology suggest that improved patient education and communication between healthcare providers and patients could dramatically enhance treatment satisfaction and overall quality of life.
If you would like to schedule an interview with one of the researchers, please contact Katelyn Deckelbaum, [email protected].
-GW-
RSS